Mode
Text Size
Log in / Sign up

Hypophosphatemia during KRT linked to fewer ventilator-free days in critically ill patientsLow phosphate during dialysis linked to fewer ventilator-free days

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider monitoring phosphate levels during KRT, as hypophosphatemia is associated with fewer ventilator-free days, but causality is unproven.

This post hoc observational study analyzed data from 1,942 critically ill patients in the STARRT-AKI trial who received kidney replacement therapy (KRT). Among them, 634 developed hypophosphatemia (serum phosphate <0.7 mmol/L) during KRT. The primary outcome was ventilator-free days (VFD) at 28 days.

Incident hypophosphatemia was associated with fewer VFD (beta = 0.91; 95% CI, 0.87-0.95; P < 0.001). Severe hypophosphatemia (<0.5 mmol/L) showed a similar association (beta = 0.87; 95% CI, 0.82-0.93; P < 0.001). The combined outcome of 28-day survival and fewer ventilator days was 27% lower in patients with incident hypophosphatemia and 25% lower in those with severe hypophosphatemia.

No association was found between hypophosphatemia and 90-day mortality or KRT dependence at 90 days. Safety data were not reported.

Key limitations include selection bias and unmeasured confounding. As a post hoc observational analysis, these findings do not establish causality. Clinicians should interpret the association cautiously and consider monitoring phosphate levels during KRT, but randomized trials are needed to confirm any causal relationship.

For critically ill patients on kidney replacement therapy, a common complication may be quietly making recovery harder. A new analysis of data from the STARRT-AKI trial looked at what happens when phosphate levels drop too low during treatment.

Among 1,942 trial participants, 634 developed hypophosphatemia (low phosphate). Those patients had fewer ventilator-free days at 28 days. The effect was even stronger for severe hypophosphatemia. Patients with low phosphate were also 27% less likely to survive and be off the ventilator at 28 days.

However, low phosphate was not linked to higher death rates at 90 days or to long-term kidney dependence. This is an observational analysis, so it cannot prove cause and effect. The findings are limited by potential selection bias and unmeasured factors.

The results suggest that keeping phosphate levels in check during kidney therapy might matter for recovery, but more research is needed to confirm whether treating low phosphate improves outcomes.

What this means for you:
Low phosphate during kidney therapy may slow recovery, but cause isn't proven.

Study Details

Study typeRct
Sample sizen = 634
EvidenceLevel 2
PublishedMay 2026
View Original Abstract ↓
RATIONALE & OBJECTIVE: Critically ill patients receiving kidney replacement therapy (KRT), especially continuous KRT (CKRT), have a high risk of hypophosphatemia due to extracorporeal losses, which may contribute to muscle weakness and prolonged respiratory failure. This study evaluated the relationship between incident hypophosphatemia and respiratory function in these patients. STUDY DESIGN: Post hoc observational study of STARRT-AKI Trial participants. SETTING & PARTICIPANTS: Eligible trial participants (1) received CKRT >24 hours or intermittent hemodialysis (IHD) or sustained low-efficiency dialysis (SLED) for >1 session, (2) had a serum phosphate level ≥ 0.5 mmol/L on the day of KRT initiation, and (3) had ≥1 serum phosphate measurement during KRT. EXPOSURE: Hypophosphatemia (<0.7 mmol/L) and severe hypophosphatemia (<0.5 mmol/L) during KRT. OUTCOME: Primary outcome was ventilator-free days (VFD) at 28 days of follow-up. Secondary outcomes included mortality and KRT dependence at 90 days. ANALYTICAL APPROACH: A truncated hurdle model was fit to describe clinical characteristics associated with hypophosphatemia. Adjusted analyses of VFD used an inverse probability weighted zero-inflated negative binomial model and a win-ratio analysis. Secondary outcomes were assessed with logistic regression. RESULTS: Of 1,942 trial participants, 634 patients (32.6%) developed hypophosphatemia, and 192 patients (9.9%) developed severe hypophosphatemia. Clinical factors independently associated with incident hypophosphatemia during KRT were female sex, lower body weight, lower serum phosphate levels at KRT initiation, CKRT as the initial KRT modality, and randomization to accelerated KRT initiation. Incident hypophosphatemia and severe hypophosphatemia were associated with fewer VFD at 28 days (β, 0.91 [95% CI, 0.87-0.95] and β, 0.87 [95% CI, 0.82-0.93], respectively; P < 0.001 for both). By win-ratio for any random pair of patients, those with incident hypophosphatemia and severe hypophosphatemia had a 27% and 25% lower likelihood of combined 28-day survival and fewer days on the ventilator, respectively. There was no association between hypophosphatemia and 90-day mortality or KRT dependence. LIMITATIONS: Selection bias and unmeasured confounding. CONCLUSIONS: Incident hypophosphatemia during KRT was independently associated with fewer VFD at 28 days.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.